Humanigen — Technical Presentation (March 2021)
12 slides from Humanigen's technical presentation, Mar 29, 2021
Slide 1: Humanigen Lenzilumab Phase 3 Results 3.29.21
Humanigen Lenzilumab Phase 3 Results 3.29.21
Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 Cautionary Note Regarding Forward - Looking Statements All statements other than statements of historical facts contained in this presentation are forward - looking statements . Forward - looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding f
Slide 3: Lenzilumab Overview
3 Lenzilumab Overview Lenzilumab is administered intravenously in three equal infusions completed in a single day Humaneered ® Best - in - Class Antibody x Neutralizes GM - CSF to prevent and treat Cytokine Storm x Reduced immunogenicity x Highest binding affinity x Slowest off - rate Dosing Regime
Slide 4: GM-CSF: A Driver of COVID-19
4 GM - CSF: A Driver of COVID - 19 • UK government - funded, independent study linked GM - CSF to severe COVID - 19 • Largest confirmatory inflammatory mediator study conducted to date • GM - CSF associated with inflammatory and thrombotic consequences of the immune response • GM - CSF levels detect
Slide 5: Lenzilumab Phase 3 Study Design
5 Lenzilumab Phase 3 Study Design Early intervention with lenzilumab to prevent and treat Cytokine Storm and prevent progression to invasive mechanical ventilation (IMV) and/or death • Randomized , double - blind, placebo - controlled, multi - center pivotal trial NCT 04351152 • All subjects receive
Slide 6: Demographics and Baseline Characteristics (mITT Population)
6 Demographics and Baseline Characteristics ( mITT Population) Characteristics Lenzilumab (N=236) Placebo (N=243) Overall (N=479) Age Mean (SD) 60.5 (13.5) 60.5 (14.3) 60.5 (13.9) Median (Min - Max) 62.0 (28 - 98) 62.0 (22 - 96) 62.0 (22 - 98) < 65 years old (%) 60.2 58.4 59.3 ≥65 years old (%) 39.8
Slide 7: Primary Endpoint: Ventilator-Free Survival (mITT Population)
7 Primary Endpoint: Ventilator - Free Survival ( mITT Population) Endpoint Hazard Ratio (95%CI) Lenzilumab vs Placebo Kaplan - Meier Event Estimate (95%CI) Lenzilumab Placebo p value 1 ° Ventilator - Free Survival (%) 1.54 (1.03 – 2.33) 15.6 (11.5 – 21.0) 22.1 (17.4 – 27.9) 0.0365 2 ° Survival (%) 1
Slide 8: Ventilator-Free Survival: A Surrogate for Survival
8 Ventilator - Free Survival: A Surrogate for Survival Ventilator - free survival may act as a surrogate e ndpoint for survival • Hazard ratio (HR) for ventilator - free survival approximates the HR for survival in the RECOVERY studies • Ventilator - free survival may provide a signal of survival be
Slide 9: Safety: Balanced Between Treatment Arms
9 Safety: Balanced Between Treatment Arms Characteristics Lenzilumab (N=255) Subjects n, % Placebo (N=257) Subjects n, % Overall (N=512) Subjects n, % Serious Adverse Events 63 (24.7) 76 (29.6) 139 (27.1) Respiratory 60 (23.5) 67 (26.1) 127 (24.8) Cardiac 12 (4.7) 13 (5.1) 25 (4.9) Infection/Infesta
Slide 10: Summary
10 Summary COVID - 19 • Neutralizes GM - CSF, a driver of Cytokine Storm • Prevents and treats Cytokine Storm to reduce progression to IMV and/or death • For newly hospitalized and hypoxic patients with COVID - 19 pneumonia • Convenient dosing regimen to which other treatments, including steroids an
Slide 11: Timeline
11 Timeline 2021 Topline COVID - 19 Phase 3 Results Pre - EUA Meetings With FDA EUA Application EUA Granted Assuming Emergency Use Authorization by FDA Lenzilumab Distribution Update CMC ACTIV - 5 March 29, 2021 Submit BLA
Slide 12: Humanigen Lenzilumab Phase 3 Results
12 Humanigen Lenzilumab Phase 3 Results